Houston, TX: Biostate AI, a leading innovator in RNA sequencing and AI-powered precision medicine, has announced a major global expansion following its $12 million Series A funding round.
With new partnerships in the United States, India, and China, the company is rapidly scaling its mission to democratize personalized healthcare by tailoring diagnostics and treatments to specific populations.
At the heart of Biostate AI’s approach is the use of RNA sequencing – a real-time snapshot of gene expression – to build predictive AI models for drug development, therapy selection, and health forecasting.
Also Read: AFMC Pune Advances Military Medicine with AI, Genomics, Simulation Labs
This methodology underpins its expanding network of collaborations across three continents, significantly enhancing its global health data capabilities.
In India, Biostate AI has launched Bayosthiti, a wholly owned subsidiary focused on developing precision diagnostics for cancer and cardiovascular diseases. By partnering with major hospital systems and cancer institutions, Bayosthiti is addressing a pressing need in a country where over 1.4 million new cancer cases are reported annually.
Co-founder and CTO Ashwin Gopinath, a former MIT professor, emphasized, “We’re applying proven RNAseq technologies to India’s unique clinical setting, enabling insights tailored to its population.”
In China, Biostate AI has entered a joint venture with Kindstar Global Gene Technology, a clinical diagnostics leader with a network spanning over 3,000 hospitals.
The initiative will adapt Biostate’s RNA sequencing and AI analysis platform to local disease patterns, initially targeting autoimmune diseases, oral cancer, diabetes, lymphoma, and post-transplant care. “This partnership offers unmatched scale and clinical depth,” said Co-founder and CEO David Zhang.
Meanwhile, in the U.S., Biostate AI is collaborating with Mass General Brigham to refine the use of immune checkpoint inhibitors in melanoma treatment. The project aims to improve treatment response predictions and reduce adverse effects by analyzing thousands of tumor and blood samples through AI. The goal is to generalize this diagnostic model to other tumor types in the future.
Biostate AI: Patents in RNA Sequencing and AI
Since its founding in 2023, Biostate AI has filed over a dozen patents in RNA sequencing and AI, and has worked with more than 100 research groups in the U.S.
Also Read: CSIR-IGIB Opens India’s First National Biobank to Advance Precision Medicine
The addition of Prasad Chintamaneni, former President at Cognizant and current Senior Advisor at New Mountain Capital, to its board underscores its commitment to scaling with strategic vision.
Biostate AI’s cross-border collaborations represent a shift in healthcare – from a one-size-fits-all model to one that prioritizes biological and geographic specificity. “Health is both hyper-local and global,” said Gopinath. “Our AI models reflect that duality, ensuring personalized treatments are accessible and cost-effective.”
By reducing the cost of innovation and focusing on region-specific diagnostics, Biostate AI is working toward a future where the benefits of precision medicine are not limited by geography or affordability.
